MRNA
Moderna raises its annual revenue forecast on 6 November 2026
On 6 November 2026, Moderna raised its sales forecast for the year. According to the media, the group is relying on demand for Covid-19 vaccines abroad, after earnings that beat expectations.
By Yvan T., published
The facts
On 6 November 2026, Moderna raised its annual revenue forecast, according to Boursorama (articles at 1:00pm and 2:16pm). The outlet attributes the upgrade to demand for Covid-19 vaccines abroad.
According to Quartz en Français (2:42pm), the revision followed the publication of earnings that beat analysts’ expectations.
The available excerpts give neither the new forecast figure, nor the previous range, nor the level of earnings reported, nor the accounting period concerned. They also do not specify which countries are driving the demand. These points are therefore not documented here.
Our take
This section is a personal analysis, not a reported fact. A forecast upgrade accompanied by better-than-expected earnings is a rather favourable signal: management says it is confident enough to aim higher, and results have beaten the consensus.
But the information remains thin. Without the size of the upgrade, the margin generated or the share price reaction, it is impossible to judge whether the news was already priced in. The mention of foreign demand also leaves an open question: is this lasting support or one-off orders? The sources do not settle it.
In the absence of figures, I do not form a firm opinion on the stock and I do not offer a target price. It would be necessary to read Moderna’s full press release, with the breakdown by product and by geographic area, before drawing a conclusion.
Risks to watch
Covid-19 vaccine sales remain dependent on public demand and vaccination campaigns, which can vary from one year to the next. Part of the increase could also be one-off, which the sources do not allow us to rule out. Finally, the absence of precise figures in the available excerpts limits any reliable assessment.
Sources
- Moderna relève sa prévision de chiffre d'affaires avec la demande de vaccins COVID-19 à l'étranger
- Moderna revoit à la hausse ses prévisions de chiffre d'affaires annuel grâce à la forte demande de vaccins con
- Moderna a relevé ses prévisions de ventes annuelles après un bénéfice supérieur aux attentes.
Information from these sources is summarised and rewritten. It has not been independently verified beyond cross-checking between sources; where the reliability of a piece of information is in doubt, the article says so.
Transparency
- AuthorTo be completed, Founder and author of the site, private investor.
- Conflicts of interestOn the publication date, holds no position in Moderna. The site receives no payment from the companies it covers. The author refrains from any transaction in a stock covered 24 hours before and 48 hours after publication.
- MethodCompilation of public information dated November 6, 2026 (sources listed above). The facts reported are kept separate from the analysis, which expresses the author's view. Full methodology.
- Artificial intelligenceText written with an artificial intelligence tool from the sources cited and published automatically, without prior human review.
- History
General information, not personalised investment advice: this article does not take your situation into account. Investing in shares carries a risk of capital loss. Past performance is not a reliable indicator of future performance. Read the full risk warning.